Late-onset complications with bendamustine versus CHOP or CVP based chemoimmunotherapy in indolent Non-Hodgkin’s lymphoma

References

• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–1210.
   PubMed Web of Science ®Google Scholar
• Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944–2952.
   PubMed Web of Science ®Google Scholar
• Armitage JO, Gascoyne RD, Lunning MA, et al. Non-Hodgkin lymphoma. Lancet. 2017;390(10091):298–310.
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Gordon LI, Abramson JS, et al. NCCN clinical practice guidelines in oncology: B-cell lymphomas. Version 4.2020. Plymouth Meeting, PA: National Comprehensive Cancer Network; 2020.
   Google Scholar
• Kumar SK, Callander NS, Baljevic M, et al. NCCN clinical practice guidelines in oncology: Waldenström’s macroglobulinemia/lymphoplasmacytic lymphoma. Version 1.2021. Plymouth Meeting, PA: National Comprehensive Cancer Network; 2020.
   Google Scholar
• Burke JM, van der Jagt RHC, Kahl BS, et al. Differences in quality of life between bendamustine-rituximab and R-CHOP/R-CVP in patients with previously untreated advanced indolent non-Hodgkin lymphoma or mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2016;16(4):182–190.e1.
   PubMed Web of Science ®Google Scholar
• Hiddeman W, Barbui AM, Canales MA, et al. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the gallium study: influence of chemotherapy on efficacy and safety. J Clin Oncol. 2018;36(23):2395–2404.
   PubMed Web of Science ®Google Scholar
• Flinn IW, van der Jaft R, Kahl B, et al. First-line treatment of patients with indolent non-hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol. 2019;37(12):984–991.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Maschmeyer G, Ganser A, et al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: nine-year updated results from the StiL NHL1 study [abstract]. J Clin Oncol. 2017;35(15_suppl)#:7501–7501.
   Web of Science ®Google Scholar
• Olszewski AJ, Reagan JL, Castillo JJ. Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas. Am J Hematol. 2018;93(1):E1–E32.
   PubMed Web of Science ®Google Scholar
• Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331–1344.
   PubMed Web of Science ®Google Scholar
• Carter SJ, Bernstein SH, Friedberg JW, et al. Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma. Leuk Res. 2011;35(11):e223–e224.
   PubMed Web of Science ®Google Scholar
• Gafter-Gvili A, Gurion R, Raanani P, et al. Bendamustine-associated infections-systematic review and meta-analysis of randomized controlled trials. Hematol Oncol. 2017;35(4):424–431.
   PubMed Web of Science ®Google Scholar
• Gafter‐Gvili A, Ribakovsky E, Mizrahi N, et al. Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi‐center study. Leuk Lymphoma. 2016;57(1):63–69.
   PubMed Web of Science ®Google Scholar
• Fung M, Jacobsen E, Freedman A, et al. Increased risk of infectious complications in older patients with indolent Non-Hodgkin lymphoma exposed to bendamustine. Clin Infect Dis. 2019;68(2):247–255.
   PubMed Web of Science ®Google Scholar
• Abkur TM, Saeed M, Ahmed SZ, et al. Pneumocystis jiroveci prophylaxis in patients undergoing Bendamustine treatment: the need for a standardized protocol. Clin Case Rep. 2015;3(4):255–259.
   PubMed Web of Science ®Google Scholar
• Hiraoka N, Kikuchi J, Yamauchi T, et al. Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies. PLoS One. 2014;9(3):e90675.
   PubMed Web of Science ®Google Scholar
• Olszewski AJ, Butera JN, Reagan JL, et al. Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma. Am J Hematol. 2020;95(4):354–361.
   PubMed Web of Science ®Google Scholar
• Harris PA, Taylor R, Thielke R, et al. Research Electronic Data Capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support . J Biomed Inform. 2009;42(2):377–381.
   PubMed Web of Science ®Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813–1821.
   PubMed Web of Science ®Google Scholar
• Kakar A, Beri R, Byotra SP, et al. Absolute lymphocyte count: a cost-effective method of monitoring HIV-infected individuals. Indian J Pathol Microbiol. 2011;54(1):107–111.
   PubMed Web of Science ®Google Scholar
• Kelesidis T, Daikos G, Boumpas D, et al. Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis. 2011;15(1):e2–e16.
   PubMed Web of Science ®Google Scholar
• Rashidi A, Oak E, Bartlett NL. Maintenance rituximab every 2 months is more toxic than every 3 months in patients with non-Hodgkin lymphoma. Blood. 2015;125(21):3354–3355.
   PubMed Web of Science ®Google Scholar
• Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42–51.
   PubMed Web of Science ®Google Scholar
• Hill BT, Nastoupil L, Winter AM, et al. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. Br J Haematol. 2019;184(4):524–535.
   PubMed Web of Science ®Google Scholar
• Baden LR, Swaminathan S, Almyroudis NG, et al. NCCN clinical practice guidelines in oncology: prevention and treatment of cancer-related infections. Version 2.2020. Plymouth Meeting, PA: National Comprehensive Cancer Network. 2020.
   Google Scholar
• Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018;36(30):3043–3054.
   PubMed Web of Science ®Google Scholar
• Joshi KP, Atwal D, Siegel ER, et al. Absolute lymphocyte count (ALC) as predictor of Pneumocystis jiroveci Pneumonia (PCP) infection in patients on immune checkpoint inhibitors (ICPi). J Clin Oncol. 2019;37(15_suppl):e14255.
   Web of Science ®Google Scholar